We are a cell therapy company focused on immunotherapy. Since our inception, we have been involved with the development of proprietary immune system management technology licensed from Yeda Research & Development Company Limited (“Yeda”), the commercial arm of the Weizmann Institute of Technology, Israel.
Company profile
Ticker
CLCS
Exchange
Website
CEO
Itamar Shimrat
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
TICKET TO SEE, INC.
SEC CIK
CLCS stock data
Latest filings (excl ownership)
8-K
Other Events
9 Apr 24
NT 10-K
Notice of late annual filing
1 Apr 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
D
Indefinite amount in debt / options / securities to be acquired, sold $3.91 mm, 48 investors
6 Oct 23
10-Q
2023 Q2
Quarterly report
19 Sep 23
10-Q
2023 Q1
Quarterly report
23 Aug 23
NT 10-Q
Notice of late quarterly filing
15 Aug 23
10-K
2022 FY
Annual report
7 Aug 23
NT 10-Q
Notice of late quarterly filing
16 May 23
NT 10-K
Notice of late annual filing
31 Mar 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q1 2021
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|